He relapsed twice after reinitiation of the drug [136] Another case (published in 2021) introduced a 71-year-old male patient with PsA who was treated with secukinumab (IL-17A inhibitor), which was later switched to adalimumab (TNF-α inhibitor), while developing subacute thyroiditis. Here, IL17A is linked to subacute thyroiditis.